Go Pro
NASDAQ:NAGE

Niagen Bioscience Q2 2026 Earnings Report

Niagen Bioscience logo
$3.29 +0.08 (+2.49%)
As of 08/28/2026 04:00 PM Eastern

Niagen Bioscience EPS Results

Actual EPS
$0.01
Consensus EPS
$0.01
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

Niagen Bioscience Revenue Results

Actual Revenue
$29.78 million
Expected Revenue
$29.95 million
Beat/Miss
Missed by -$170.00 thousand
YoY Revenue Growth
N/A

Niagen Bioscience Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Niagen Bioscience Earnings Headlines

Niagen Bioscience Inc NAGE
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
See More Niagen Bioscience Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Niagen Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Niagen Bioscience and other key companies, straight to your email.

About Niagen Bioscience

Niagen Bioscience (NASDAQ:NAGE) is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

View Niagen Bioscience Profile